Displaying 26 (all) recruiting clinical trials.
-
AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients with Advanced Solid Tumors with AKT1 E17K Mutation
This trial is designed to test the effectiveness of ALTA2618 in patients with advanced solid tumors that have a specific genetic mutation (AKT1 E17K). The ...
Phase
Interventional
-
Phase 3 Randomized Open-label Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)
This is a Phase 3 trial testing whether the study medicine sacituzumab tirumotecan (an antibody-drug conjugate, also known as sac-TMT, or MK-2870), when given in ...
Phase
Interventional
-
A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator s Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GOG 3107)
This study is being done to compare a new treatment, Rina-S, to standard chemotherapy in patients with a type of ovarian cancer that no longer ...
Phase
Interventional
-
A Phase 2/3 Multicenter Randomized Study of Raludotatug Deruxtecan (R-DXd) a CDH6-directed Antibody-drug Conjugate in Subjects with Platinum-resistant High-grade Ovarian Primary Peritoneal or Fallopian Tube Cancer
This is a Phase 2/3 study aimed at learning more about the study medicine Raludotatug Deruxtecan (R-DXd) as a treatment for ovarian cancer patients ...
Phase
Interventional
-
A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)
This is a Phase 3 study testing whether the study medicine MK-2870 is safer and more effective compared to the doctor's choice of other ...
Phase
Interventional
-
A Phase 2 Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1)
This is a phase 2 study to test whether the new study medicine, INCB123667 (CDK2 inhibitor), is safe and effective in patients with platinum-resistant ovarian ...
Phase
Interventional
